World Diabetes Day | Avoid the Sweet Trap — ACRO Fuels Innovation in Diabetes Drug Development

Every year on November 14, World Diabetes Day serves as a reminder that diabetes management goes beyond blood glucose control — it’s about optimizing overall metabolic health and related biomarkers. As the global prevalence of diabetes continues to rise, the importance of scientific research and innovative drug development has become increasingly evident.

https://www.vecteezy.com/vector-art/6244491-diabetes-flat-infographics

Symptoms, risk factors, prevention, and complications of diabetes

Diabetes is a chronic metabolic disease characterized by elevated blood glucose levels. Persistent hyperglycemia can lead to serious complications, including cardiovascular and cerebrovascular diseases, kidney damage, retinopathy, and neuropathy, while also imposing a significant burden on quality of life and healthcare systems. Based on etiology, diabetes is classified as Type 1 Diabetes (T1D) and Type 2 Diabetes (T2D), which differ markedly in pathogenesis, treatment approaches, and drug development strategies.

Pathophysiology of T1D: Autoimmune-Mediated Insulin Deficiency

T1D is an autoimmune disorder in which the immune system aberrantly attacks pancreatic β-cells, resulting in severe or complete insulin deficiency. Insulin is the key hormone regulating blood glucose, and its absence directly leads to hyperglycemia, disrupting overall metabolic balance. T1D predominantly affects children and adolescents and is therefore often referred to as “juvenile diabetes.” Although T1D accounts for only about 5–10% of all diabetes cases, it has an acute onset, progresses rapidly, and requires lifelong insulin therapy for blood glucose management. Currently, there are approximately 10 million people living with T1D worldwide. In recent years, incidence rates have been rising in certain regions, such as North America and Europe, particularly among children, driven by a combination of genetic susceptibility, environmental factors, and early viral infections.

https://doi.org/10.1016/j.cmet.2019.11.017

Mechanisms of immune tolerance and therapeutics in T1D

The cornerstone of T1D treatment remains insulin replacement therapy. Advances in technology, particularly the integration of insulin pumps with continuous glucose monitoring (CGM) systems, have enabled “closed-loop” glucose management, offering patients more precise and convenient glycemic control. Current therapeutic strategies for T1D aim to restore immune tolerance or selectively suppress autoimmune responses to preserve residual β-cell function. Approaches under investigation include: immune checkpoint modulation (e.g., the CTLA-4 inhibitor Abatacept), cytokine-targeted therapies (e.g., IL-6R and TNF-α antagonists), lymphocyte-directed interventions (Teplizumab, an anti-CD3 monoclonal antibody, is currently the only approved drug for delaying T1D onset in high-risk individuals), and metabolic–immune combination therapies (e.g., GLP-1R agonists).

Approved originator biologics for T1D (Source: Pharmacodia)

Research trends are increasingly focused on combination therapies (such as Teplizumab plus IL-2) and integration with artificial pancreas technology. However, key challenges remain, including maintaining long-term efficacy (limited by the “honeymoon period”), patient stratification (relying on autoantibody profiles and HLA typing), and long-term safety considerations (infection and cancer risk). Novel targeted agents, such as CD40L inhibitors, are in clinical trials, while stem cell transplantation combined with localized immune modulation shows significant promise. Overall, T1D drug development is evolving from pure insulin replacement toward a comprehensive strategy of immune modulation plus β-cell restoration. Future multi-targeted approaches that combine immune suppression, cell protection, and regeneration may ultimately enable a shift from symptomatic management to true disease modification.

Pathophysiology of T2D: Insulin Resistance and Metabolic Dysregulation

Type 2 diabetes (T2D) is the most common form of diabetes, accounting for over 90% of cases worldwide. It is characterized by the coexistence of insulin resistance and progressive β-cell dysfunction. In the early stages of T2D, insulin secretion remains sufficient, but peripheral tissues—particularly the liver, muscle, and adipose tissue—exhibit reduced insulin sensitivity, resulting in decreased glucose uptake and increased hepatic glucose production, which together drive hyperglycemia. As the disease progresses, β-cell function gradually declines, insulin secretion becomes insufficient, and glycemic control deteriorates further. The development of T2D is closely associated with genetic predisposition, obesity, sedentary lifestyle, dietary imbalance, and chronic low-grade inflammation. According to the International Diabetes Federation (IDF), over 500 million people worldwide currently live with T2D, with numbers projected to exceed 600 million by 2045.

https://doi.org/10.3390/nu14183775

Main actions of glucagon, GLP-1, and GIP hormones

Chronic hyperglycemia can lead to serious complications, including cardiovascular and cerebrovascular disease, diabetic nephropathy, retinopathy, and neuropathy. Unlike T1D, T2D management focuses on improving insulin sensitivity and enhancing insulin secretion. In the early stages, lifestyle interventions—such as diet, exercise, and weight management—can significantly improve glycemic control. Pharmacologic therapy has evolved from traditional oral hypoglycemic agents (e.g., metformin, sulfonylureas) to novel targeted therapies. In recent years, innovative treatments such as GLP-1R agonists (e.g., semaglutide), dual GIPR/GLP-1R agonists (e.g., tirzepatide), SGLT2 inhibitors (e.g., empagliflozin), and combination strategies (e.g., SGLT2 plus DPP-4 inhibitors) have not only achieved excellent glycemic control but also provided additional metabolic benefits, including weight reduction and cardio-renal protection, ushering in a new era of multi-targeted, system-level T2D therapy.

Approved originator biologics for T2D (Source: Pharmacodia)

ACROBiosystems Pioneers Diabetes Therapeutics with Innovative Solutions

ACROBiosystems has launched comprehensive drug development solutions addressing the urgent needs in diabetes therapy, covering both autoimmune (T1D) and metabolic (T2D) diseases. Our portfolio spans key target proteins, high-specificity antibodies, stable expression cell lines, high-sensitivity detection kits, and a suite of analytical tools, complemented by professional customized technical services, providing robust support and efficient acceleration for your drug and therapy development programs.

Hot T1D Target Recommendations

Hot T2D Target Recommendations

Related Articles

>> World Ankylosing Spondylitis Day | ACRO Stands with You in Safeguarding Spinal Health

>> World Lupus Day | ACRO Stands with You in the Fight Against SLE

>> World Inflammatory Bowel Disease Day | ACRO Stands with You in Safeguarding Intestinal Health

>> World Multiple Sclerosis Day | ACRO Stands with You in the Silent Battle of the Central Nervous System

>> World Myasthenia Gravis Day | ACRO Stands with You in Protecting Muscle Health

>> World Sjögren’s Day | Advancing Together with ACRO to Uncover the Truth Behind Dryness

>> World Atopic Dermatitis Day | ACRO Supporting an Itch-Free Life

>> World Arthritis Day | ACRO with You to Safeguard Joint Health

>> World Psoriasis Day | ACRO Partnering with You to Advance Skin Health

>> ComboX, A Combination of Universal Solutions

References